Physician profile

Vinson Albert Smith

Orthopaedic Surgery · Roswell, GA

NPI 1669477345

$2,371.90

in general payments reported to CMS, 2019-2025

10 companies · $13.61 in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$62.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Smith+Nephew, INC. $1,074.65 2019
Pacira Pharmaceuticals Incorporated $852.42 2022-2025 Zilretta
Depuy Synthes Sales INC. $124.73 2020
Acumed LLC $109.73 2019
Ermi LLC $53.10 2019-2024
Trice Medical, INC. $48.62 2019
Fidia Pharma USA INC. $43.84 2020-2024 Hymovis
Zimmer Biomet Holdings, INC. $28.08 2020
Bioventus LLC $18.77 2019
Upsher-Smith Laboratories LLC $17.96 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vinson Albert Smith

$2,371.90

in general payments reported 2019-2025

Years
2019-2025
Top company
Smith+Nephew, INC.

https://glasscript.com/doctor/75014/vinson-albert-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.